Search Results - "Wild, James E."

Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives by Hale, Martin E., Wild, James E., Yamada, Tadaaki, Yokota, Takaaki, Tack, Jan, Andresen, Viola, Drewes, Asbjørn Mohr

“…Background: Two studies demonstrated the efficacy and safety of naldemedine in adult patients with chronic non-cancer pain and opioid-induced constipation…”
Get full text

Naldemedine Is Effective in the Treatment of Opioid-Induced Constipation in Chronic Non-Cancer Pain in Subjects With or Without Inadequate Response to Laxatives: 431 by Tack, Jan, Hale, Martin E., Krauter, Eric, Yamada, Tadaaki, Yokota, Takaaki, Wild, James E.

“…Introduction: Opioid-induced constipation (OIC), a common side effect of opioid utilization in treating chronic non-cancer pain, is caused by the action of…”
Get full text

Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain by Wild, James E., Grond, Stefan, Kuperwasser, Brigitte, Gilbert, Jane, McCann, Bettyanne, Lange, Bernd, Steup, Achim, Häufel, Thomas, Etropolski, Mila S., Rauschkolb, Christine, Lange, Robert

“…Background:  Tapentadol is a novel, centrally acting analgesic with 2 mechanisms of action: µ‐opioid receptor agonism and norepinephrine reuptake inhibition…”
Get full text

Single‐Entity Hydrocodone Extended‐Release Capsules in Opioid‐Tolerant Subjects with Moderate‐to‐Severe Chronic Low Back Pain: A Randomized Double‐Blind, Placebo‐Controlled Study by Rauck, Richard L., Nalamachu, Srinivas, Wild, James E., Walker, George S., Robinson, Cynthia Y., Davis, Charles S., Farr, Stephen J.

“…Objective A single‐agent, extended‐release formulation of hydrocodone (HC) has been developed for treatment of chronic moderate‐to‐severe pain. This study was…”
Get full text

A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy by Webster, Lynn R, Hale, Martin E, Yamada, Tadaaki, Wild, James E

“…Naldemedine, an oral, peripherally acting μ-opioid receptor antagonist approved for the treatment of opioid-induced constipation (OIC), is renally excreted…”
Get full text

Effect of Naldemedine on Frequency of Spontaneous Bowel Movements and Associated Symptoms: 479 by Wild, James E., Hale, Martin, Yamada, Tadaaki, Ferreira, Juan Camilo Arjona

Get full text

Safety and Efficacy of Naldemedine in Treatment of Opioid-Induced Constipation in Chronic Noncancer Subjects Determined to Be Laxative Inadequate Responders: An Exploratory Analysis from Two Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Studies by Krauter, Eric, Hale, Ma, Wild, James E, Yamada, Tadaaki, Yokota, Takaaki, Tack, Jan

“…Introduction: Opioids effectively treat pain yet may be limited by side effects, including constipation. Naldemedine is an oral, peripherally acting…”
Get full text

Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain: Long-term Safety of Tapentadol ER for Chronic Pain by Wild, James E., Grond, Stefan, Kuperwasser, Brigitte, Gilbert, Jane, McCann, Bettyanne, Lange, Bernd, Steup, Achim, Häufel, Thomas, Etropolski, Mila S., Rauschkolb, Christine, Lange, Robert

Get full text